Abstract: The present invention provides a method for providing alpha-1 antitrypsin (?1-AT) to a subject, in particular a method for treating or preventing a disorder of disease associated with ?1-AT deficiency in the subject, wherein the method comprises providing, subcutaneously, a therapeutically or prophylactically effective amount of ?1-AT to the subject. Also provided is a composition and article of manufacture comprising ?1-AT, in particular a formulation suitable for subcutaneous administration of ?1-AT.

Abstract: A method for administration of an IgG preparation by an intradermal (ID) route to a subject includes loading with a volume of the IgG preparation an ID delivery device including needles, applying the device to a skin delivery site, using the device to allow dermal penetration of the needles, delivering the volume of the IgG preparation at the skin delivery site, and removing the injection delivery device. The method can be used in the treatment of a disease, such as an immunodeficiency.

Abstract: The present invention provides a method for providing alpha-1 antitrypsin (?1-AT) to a subject, in particular a method for treating or preventing a disorder or disease associated with ?1-AT deficiency in the subject, wherein the method comprises providing, subcutaneously, a therapeutically or prophylactically effective amount of ?1-AT to the subject. Also provided is a composition and article of manufacture comprising ?1-AT, in particular a formulation suitable for subcutaneous administration of ?1-AT.

Abstract: A method for administration of an IgG preparation by an intradermal (ID) route to a subject includes loading with a volume of the IgG preparation an ID delivery device including needles, applying the device to a skin delivery site, using the device to allow dermal penetration of the needles, delivering the volume of the IgG preparation at the skin delivery site, and removing the injection delivery device. The method can be used in the treatment of a disease, such as an immunodeficiency.

Abstract: A method of controlling signal termination includes providing first logic for selectively terminating signals received at a first device on a bidirectional data bus, providing second logic for selectively terminating signals received at a second device on the bidirectional data bus, sending first signals from the first device to the second device on the bidirectional data bus at a first speed, stopping the sending of the first signals, after stopping the sending of the first signals, enabling the second logic and shifting a reference voltage of the second device from a first level to a second level, after enabling the second logic at the second device, sending second signals from the first device to the second device on the bidirectional data bus at a higher speed, and controlling the first logic based on a speed of signals received at the first device on the bidirectional data bus.

Abstract: A method of controlling signal termination includes providing first logic for selectively terminating signals received at a first device on a bidirectional data bus, providing second logic for selectively terminating signals received at a second device on the bidirectional data bus, sending first signals from the first device to the second device on the bidirectional data bus at a first speed, stopping the sending of the first signals, after stopping the sending of the first signals, enabling the second logic and shifting a reference voltage of the second device from a first level to a second level, after enabling the second logic at the second device, sending second signals from the first device to the second device on the bidirectional data bus at a higher speed, and controlling the first logic based on a speed of signals received at the first device on the bidirectional data bus.

Abstract: A method of controlling signal termination includes providing first logic for selectively terminating signals received at a first device on a bidirectional data bus, providing second logic for selectively terminating signals received at a second device on the bidirectional data bus, sending first signals from the first device to the second device on the bidirectional data bus at a first speed, stopping the sending of the first signals, after stopping the sending of the first signals, enabling the second logic and shifting a reference voltage of the second device from a first level to a second level, after enabling the second logic at the second device, sending second signals from the first device to the second device on the bidirectional data bus at a higher speed, and controlling the first logic based on a speed of signals received at the first device on the bidirectional data bus.

Abstract: A method of controlling signal termination includes providing first logic for selectively terminating signals received at a first device on a bidirectional data bus, providing second logic for selectively terminating signals received at a second device on the bidirectional data bus, sending first signals from the first device to the second device on the bidirectional data bus at a first speed, stopping the sending of the first signals, after stopping the sending of the first signals, enabling the second logic and shifting a reference voltage of the second device from a first level to a second level, after enabling the second logic at the second device, sending second signals from the first device to the second device on the bidirectional data bus at a higher speed, and controlling the first logic based on a speed of signals received at the first device on the bidirectional data bus.

Abstract: Methods of using polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided, including methods related to vitrectomy or vitreolysis. The plasmin(ogen) molecule has a single kringel domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.

Abstract: The present invention provides a method for providing alpha-1 antitrypsin (?1-AT) to a subject, in particular a method for treating or preventing a disorder or disease associated with ?1-AT deficiency in the subject, wherein the method comprises providing, subcutaneously, a therapeutically or prophylactically effective amount of ?1-AT to the subject. Also provided is a composition and article of manufacture comprising ?1-AT, in particular a formulation suitable for subcutaneous administration of ?1-AT.

Abstract: Methods of using polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided, including methods related to vitrectomy or vitreolysis. The plasmin(ogen) molecule has a single kringel domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.

Abstract: A security architecture has an event analysis engine that acquires several tangible actions. The occur in an action space of an organization, and relate to unauthorized access to assets and reproduction of information. The event analysis engine evaluates the acquired actions based on the information stored in the database and in the context of past actions which have occurred, and determines a suitable response to the acquired action based on the evaluation.